Neuropeptide FF vs Relaxin-3 — mechanism, half-life, dosing, and research status compared. Which is right for your protocol?
Neuropeptide FF (NPFF) is an endogenous octapeptide first isolated from bovine brain in 1985 and recognized as a key endogenous anti-opioid system component. NPFF is produced in the hypothalamus, brain stem, and spinal cord and acts on NPFF1 and NPFF2 receptors (GPCRs) to oppose ...
Calculate Neuropeptide FF dose →Relaxin-3 (also called INSL7) is the most ancient member of the insulin/relaxin superfamily and is expressed predominantly in the nucleus incertus (NI) of the brainstem, a structure implicated in stress, arousal, and hippocampal theta rhythm generation. Unlike relaxin-1 and relax...
Calculate Relaxin-3 dose →| Parameter | Neuropeptide FF | Relaxin-3 |
|---|---|---|
| Category | Neuropeptide | Neuropeptide |
| Research | Research | Preclinical Research |
| Half-Life | Short (minutes) | ~30-60 minutes (estimated) |
| Typical Dose | 0.1-10 nmol (central, animal) | 100-500 pmol ICV; 1-3 nmol/kg SC |
| Frequency | Variable | Single or twice daily (preclinical) |
| Route | Intrathecal, Intracerebroventricular (research) | ICV, SC (preclinical) |
| FDA Status | Not approved | Research compound |
Use ASCEND's free reconstitution calculator to get exact syringe draw amounts for your vial.
For research use only. Not medical advice. ASCEND does not conduct or endorse any specific research protocol. Always consult relevant scientific literature and regulatory guidelines.